Telomerase is expressed in almost all cancer cells, including lung cancer, but it is not expressed in most normal cells, except in a small fraction of stem cells. Telomerase activity is needed to maintain the ends of linear chromosomes that become shortened as part of pre-neoplastic progression. Shortened telomeres and high telomerase activity almost always correlate with cancer severity in the lung. Our previous results have documented that a small molecule inhibitor of telomerase, GRN163L, can effectively prevent lung cancer metastasis in experimental xenograft mouse models. We hypothesize that there may be a window of therapeutic opportunity to eliminate residual lung cancer cells in patients without adversely compromising normal stem cell function. Our long-term goal is to determine the most effective way to combine standard chemotherapy with telomerase inhibitors clinically so as to prevent or prolong the time to relapse or progression of patients with advanced lung cancer as well as prevent recurrences in early stage non-small cell lung cancer after standard surgical resection. To accomplish this goal our specific aims are as follows:
Aim 1) To complete a Phase I sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dosage of weekly administered GRN163L in combination with paclitaxel and carboplatin in patients with advanced or metastatic non-small cell lung cancer. We will include correlative studies on circulating tumor cells (CTC) to determine if telomerase is inhibited and if the absolute number of CTCs decreases.
Aim 2) To determine if the combination of telomerase inhibitors with additional chemotherapeutic agents results in anti-lung cancer effects in preclinical models.
Aim 3) To determine if the telomerase inhibitor, GRN163L, targets the putative stem cell subpopulation of lung cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-14
Application #
8290537
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-06-27
Budget End
2012-04-30
Support Year
14
Fiscal Year
2011
Total Cost
$173,756
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867

Showing the most recent 10 out of 1059 publications